Combination therapy for advanced pancreatic cancer using Herceptin™ plus chemotherapy

International Journal of Oncology

Volumn 27, Issue 4, 2005, Pages 1125-1130

  Büchler, Peter ^a,b   Reber, Howard A ^b   Eibl, Guido ^b   Roth, Mendel A ^b   Büchler, Markus W ^a   Friess, Helmut ^a   Isacoff, William H ^b   Hines, Oscar J ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Docetaxel; Gemcitabine; Herceptin; Model; Orthotopic animal; Pancreatic cancer

Indexed keywords

AGAR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DOCETAXEL; DRUG DERIVATIVE; GEMCITABINE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TAXOID; TRASTUZUMAB;

ANIMAL; ARTICLE; ASCITES; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL SURVIVAL; CHEMISTRY; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; HUMAN; MALE; METABOLISM; MOUSE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TIME; TUMOR CELL LINE;

AGAR; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; RECOMBINANT PROTEINS; TAXOIDS; TIME FACTORS;

EID: 33644824375     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.4.1125     Document Type: Article

References (30)

1. Pegram M and Slamon D: Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 27: 13-19, 2000.
2. Slamon DJ, Godolphin,W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
4. Friess H, Wang L, Zhu Z, Gerber R, Schroder M, Fukuda A, Zimmermann A, Kore M and Buchler MW: Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. Ann Surg 230: 767-774, 1999.
5. Dugan MC, Dergham ST, Kucway R, Singh K, Biemat L, Du W, Vaitkevicius VK, Crissman JD and Sarkar FH: HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 14: 229-236, 1997.
6. Kumar R and Yarmand-Bagheri R: The role of HER2 in angiogenesis. Semin Oncol 28: 27-32, 2001.
7. Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y and Yu D: Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98: 1377-1385,2003.
8. Koukourakis MI, Simopoulos C, Polychronidis A, Perente S, Botaitis S, Giatromanolaki A and Sivridis E: The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/ VEGF pre-treatment status? Anticancer Res 23: 1673-1680, 2003.
9. Izumi Y, Xu L, Di Tomaso E, Fukumura D and Jain RK: Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280, 2002.
10. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H and Buchler MW: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358: 1576-1585, 2001.
11. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ and Buchler MW: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210, 2004.
12. Di Magno EP, Reber HA and Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterolgy 117: 1464-1484,1999.
13. Slamon D: Herceptin: increasing survival in metastatic breast cancer. Eur J Oncol Nurs 4: 24-29, 2000.
14. Slamon D and Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28: 13-19,2001.
15. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R and Slamon DJ: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96: 739-749, 2004.
16. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA and Slamon DJ: Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96: 759-769, 2004.
17. Pegram MD, Lopez A, Konecny G and Slamon DJ: Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 27: 21-25, 2000.
18. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L and Hudis CA: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595,2001.
19. Buchler P, Reber HA, Buchler MC, Roth MA, Buchler MW, Friess H, Isacoff WH and Hines OJ: Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg 5: 139-146, 2001.
20. Buchler P, Reber HA, Lavey RS, Tomlinson J, Buchler MW, Friess H and Hines OJ: Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res 120: 295-303, 2004.
21. Buchler P, Reber HA, Buchler MW, Friess H, Lavey RS and Hines OJ: Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxiainducible factor-1 and the down-regulation of VEGF gene expression. Cancer 100: 201-210, 2004.
22. Fu X, Guadagni F and Hoffman RM: A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA 89: 5645-5649, 1992.
23. Wagman R and Grann A: Adjuvant therapy for pancreatic cancer: current treatment approaches and future challenges. Surg Clin North Am 81: 667-681, 2001.
24. Van Moorsel CJ, Kroep JR, Pinedo HM, Veerman G, Voorn DA, Postmus PE, Vermorken JB, van Groeningen CJ, van der Vijgh WJ and Peters GJ: Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 10: 441-448, 1999.
25. Riou JF, Naudin A and La velle F: Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187: 164-170, 1992.
26. Bissery MC: Preclinical pharmacology of docetaxel. Eur J Cancer 31A (Suppl. 4): S1-S6, 1995.
27. Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP and Benson AB III: Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (El298). A trial of the eastern cooperative oncology group. Oncology 66: 303-309, 2004.
28. Abbruzzese JL: Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. Semin Oncol 29: 2-8, 2002.
29. Sherman WH and Fine RL: Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 60: 316-321, 2001.
30. Schneider BP, Ganjoo KN, Seitz DE, Picus J, Fata F, Stoner C, Calley C and Loehrer PJ: Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 65: 218-223, 2003.